Bridging Genomics and Proteomics: Interrogation of Prospective and Archived Samples for Population-Scale Biomarker Discovery

Personalized medicine promises to significantly improve patient outcomes, but achieving this requires a deep understanding of human health and disease mechanisms at the molecular level. The advent of the omics era, powered by Next Generation Sequencing (NGS), has revolutionized our ability to analyze genomes, epigenomes, and transcriptomes in great detail. By integrating proteomics with large-scale genomic data, we can better understand disease mechanisms, identify early biomarkers, and uncover therapeutic targets, paving the way for more effective, personalized treatments.

Olink offers a range of proteomics products to analyze and quantify proteins, facilitating advanced biomarker discovery and disease research. It integrates the selective affinity of antibodies with the resolving power of PCR and NGS, resulting in a highly sensitive, specific, and high-throughput Proximity Extension Assay (PEA). The high sensitivity and throughput of these assays require automated liquid handling systems capable of executing rapid sub-microliter transfers with exceptional precision.

In this webinar, we will discuss how the Olink Explore HT workflow, coupled with Formulatrix’s automated low-volume liquid handler, the F.A.S.T.^TM, facilitates the quantification of over 5,000 proteins from as little as three microliters of sample. 

We will also highlight the role of GENEWIZ Proteomics Solutions from Azenta Life Sciences in the FinnGen project, a large-scale genomic and proteomic study involving 500,000 Finnish citizens, including proteomic analyses of up to 20,000 individuals. These advancements underscore the transformative potential of integrating proteomic and genomic data to accelerate innovation in healthcare and disease management.